

Product Name : Cabozantinib (S-malate)

Synonyms : XL184;XL-184;Cabozantinib;XL 184


Cat No. : M10498

CAS Number : 1140909-48-3

Molecular Formula : C32H30FN3O10

Formula Weight : 635.59

Chemical Name : Butanedioic acid, 2-hydroxy-, (2S)-, compd. with N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)



Description : Cabozantinib (XL184) is a potent, multi-kinase inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50 of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively; eliminates tumor vasculature, reduces pericytes and empty basement membrane sleeves, causes widespread intratumoral hypoxia and tumor cell apoptosis, and slows regrowth of the tumor vasculature, also decreases invasiveness of primary tumors and reduces metastasis in pancreatic islet cancer; exerts marked anti-MPNST effects in vitro and in vivo. Kidney Cancer Approved

Pathway : Angiogenesis

Target : VEGFR

Receptor : AXL; c-Met; Kit; VEGFR2/KDR; VEGFR3/FLT4

Solubility : DMSO: ≥ 23 mg/mL

SMILES : COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C([C@@H](C(=O)O)O)C(=O)O

Storage : (-20°C)

Stability : ≥ 2 years

Reference :

1. You WK, et al. Cancer Res. 2011 Jul 15;71(14):4758-68. | 2. Durante C, et al. Expert Opin Investig Drugs. 2011 Mar;20(3):407-413. | 3. Torres KE, et al. Clin Cancer Res. 2011 Jun 15;17(12):3943-55. | 4. Kurzrock R, et al. J Clin Oncol. 2011 Jul 1;29(19):2660-6.